[Efficacy and tolerance of Proxen 500 mg film-coated tablets in coxarthrosis].
29 patients exhibiting primary and secondary arthritic changes in the joints (mainly patients with osteoarthritis of the hip) were treated with a new naproxen formulation (proxen 500 mg film-coated tablets). The tablets were taken twice daily and the period of observation was four weeks. Therapeutic efficacy was assessed on the basis of clinical findings (active and passive articular function and in some cases morning stiffness and articular swelling) and also the improvement in painful symptoms (night and spontaneous pain, pain on standing and walking). There was a distinct improvement in the clinical symptoms in 25 patients and unsatisfactory results were only obtained in three cases. Summing up, naproxen is a proven antirheumatic. The new formulation with the 500 mg film-coated tablet provides a simplified dosage regimen and simple therapy for the physician with increased patient compliance and a lower rate of drug intake errors.
D000328:Adult; D000368:Aged; D004304:Dosage Forms; D004361:Drug Tolerance; D005260:Female; D006621:Hip Joint; D006801:Humans; D008297:Male; D008875:Middle Aged; D009288:Naproxen / Q000008:administration & dosage* / Q000627:therapeutic use; D010003:Osteoarthritis / Q000188:drug therapy*
D004304:Dosage Forms; D009288:Naproxen
Wirksamkeit und Verträglichkeit von Proxen 500 mg-Filmtabletten bei Koxarthrose.